Browse by Series:

Emerging Agents in the Pipeline for Merkel Cell Carcinoma

Howard L. Kaufman, MD, FACS
Published: Thursday, May 04, 2017



Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses emerging agents in the pipeline for Merkel cell carcinoma.
Slider Left
Slider Right


Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses emerging agents in the pipeline for Merkel cell carcinoma.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x